FATE Therapeutics (NASDAQ: FATE) director exercises options, boosts direct stake
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
FATE Therapeutics director William H. Rastetter exercised stock options to acquire 25,000 shares of Common Stock at $1.69 per share. Following the exercise, he holds 36,331 Common shares directly. In addition, 459,272 shares are held indirectly by The Investment 2002 Trust and 146,821 shares are held indirectly by The Rastetter Family Trust, where he serves in trustee roles.
Positive
- None.
Negative
- None.
Insider Trade Summary
25,000 shares exercised/converted
Mixed
4 txns
Insider
RASTETTER WILLIAM H
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Exercise | Common Stock | 25,000 | $1.69 | $42K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct, null);
Common Stock — 36,331 shares (Direct, null);
Common Stock — 146,821 shares (Indirect, By The Rastetter Family Trust, dated 09/02/10)
Footnotes (1)
- These shares are owned of record by The Rastetter Family Trust, dated September 2, 2010 for which William H. Rastetter and Marisa Gard Rastetter serve as co-trustees. These shares are owned of record by The Investment Trust, dated November 11, 2002, for which William H. Rastetter is the sole trustee and owner. The shares subject to the option vested and became exercisable on the date of the 2017 Annual Meeting of Stockholders.
Key Figures
Option exercise shares: 25,000 shares
Exercise price: $1.69 per share
Direct common shares after transaction: 36,331 shares
+3 more
6 metrics
Option exercise shares
25,000 shares
Common Stock acquired via option exercise on 2026-05-05
Exercise price
$1.69 per share
Conversion or exercise price for 25,000-share option
Direct common shares after transaction
36,331 shares
Direct ownership following the option exercise
Investment 2002 Trust holdings
459,272 shares
Indirect ownership by The Investment 2002 Trust
Rastetter Family Trust holdings
146,821 shares
Indirect ownership by The Rastetter Family Trust
Exercise count
1 transaction
Derivative exercise or conversion events in this filing
Key Terms
Stock Option (Right to Buy), derivative security, indirect ownership, co-trustees
4 terms
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
indirect ownership financial
"ownership_type": "indirect""
co-trustees financial
"serve as co-trustees."
FAQ
What insider transaction did FATE (FATE Therapeutics) report for William H. Rastetter?
FATE reported that director William H. Rastetter exercised stock options for 25,000 shares. He converted options into common stock at $1.69 per share, increasing his directly held common shares while not reporting any open-market sales in this filing.
At what price did William H. Rastetter exercise FATE stock options?
Rastetter exercised his FATE stock options at $1.69 per share. The Form 4 shows an option exercise of 25,000 shares with a conversion or exercise price of $1.69, turning those derivative securities into directly held common stock.
Did the FATE Form 4 show any stock sales by William H. Rastetter?
The Form 4 does not report any sales of FATE shares by Rastetter. It shows an option exercise coded “M” for 25,000 shares and updated holdings, but no transactions marked as open-market sales or dispositions.